The MRSA Keratitis in Premature Infant.
- Author:
Yang Kyeung CHO
1
;
Man Soo KIM
Author Information
1. Department of Ophthalmology, St.Vincent's hospital, The Catholic University of Korea, College of Medicine, Korea. yangkyeung@hanmail.net
- Publication Type:Original Article
- Keywords:
MRSA;
Neonates
- MeSH:
Administration, Intravenous;
Amblyopia;
Anti-Bacterial Agents;
Corneal Opacity;
Diagnosis;
Humans;
Infant, Newborn;
Infant, Premature*;
Inflammation;
Keratitis*;
Keratoplasty, Penetrating;
Methicillin Resistance;
Methicillin-Resistant Staphylococcus aureus*;
Reproductive History;
Staphylococcus aureus;
Vancomycin;
Vulnerable Populations
- From:Journal of the Korean Ophthalmological Society
2003;44(9):1986-1990
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Methicillin resistant staphylococcus aureus (MRSA) keratitis is hard to treat because it has a tendency to increase resistance to almost every antibiotics. Because neonates, especially premature infants are a particulary vulnerable population, prompt diagnosis and treatment is needed. We report a case of MRSA keratitis in a premature infant, which resulted in severe corneal opacity with neovascularization. METHODS: We treated MRSA keratitis in a premature baby whose birth history is 29(+5) weeks-1.6Kg-C/S delivery. RESULTS: Conventional treatment with intravenous administration of antibiotics and topical antibiotics did not improve the corneal inflammation. Culture proven diagnosis of MRSA keratitis was made and vancomycin was started. one week after vancomycin treatment, corneal inflammation began to decrease slowly. But there remained severe corneal opacity with neovascularization. Penetrating keratoplasty and amblyopia treatment may be required in the future.
